GSK

GSK, the UK's second-largest drugmaker, is currently newsworthy due to several recent developments. Firstly, they announced a $2.2 billion acquisition of RAPT, a Californian biotech company specializing in food allergy treatments, marking the first major deal under new CEO Luke Miels. This acquisition highlights GSK's strategic focus on expanding its portfolio in innovative therapeutic areas. Secondly, GSK is involved in research and development of new antibiotics hailed as a potential 'turning point' in combating drug-resistant gonorrhea. With gonorrhea infections rising globally, particularly in Africa and the Western Pacific region, GSK's contribution to developing effective treatments is of significant public health importance. These activities demonstrate GSK's continued relevance in addressing critical healthcare challenges and its commitment to innovation within the pharmaceutical industry.